Document Detail

Eletrocardiographic monitoring in COPD patients receiving tiotropium.
MedLine Citation:
PMID:  17136986     Owner:  NLM     Status:  MEDLINE    
Tiotropium is a once-daily, inhaled anticholinergic for the treatment of chronic obstructive pulmonary disease that acts as a prolonged antagonist of the M3-receptor. To ascertain whether electrophysiologic effects can be detected following tiotropium treatment in patients with chronic obstructive pulmonary disease, serial electrocardiograms were incorporated into multiple placebo-controlled clinical trials including long-term (6 and 12-month) trials with tiotropium 18 mcg daily (n=2,128) and a 4-week dose-ranging study with tiotropium up to 36 mcg daily (n= 169). In addition, 24-hour electrocardiographic (Holter) monitoring was performed as part of a 6-week, placebo-controlled trial with tiotropium 18 mcg daily (n= 121). Electrocardiograms were performed before and up to 6 times during treatment in the 12-month trials, and before and at the end of treatment in the 6-month trials. For both the 12 and 6-month trials, electrocardiograms were recorded as adverse events if significant changes occurred, and were retrospectively sent for centralized analysis. During the 6-week trial, Holter monitoring was performed prior to the first dose and following 6 weeks of treatment. In all of these trials, no significant differences were observed in any of the electrocardiogram or Holter outcome parameters compared to placebo. Specifically, there was no clinically relevant difference in heart rate, atrio-ventricular conduction or the occurrence of ventricular or supraventricular arrhythmias. In conclusion, tiotropium was not associated with any signs of cardiac safety concerns as defined by electrocardiographic evaluations in placebo-controlled clinical trials.
Joel Morganroth; Wolfgang Golisch; Steven Kesten
Related Documents :
24351896 - The impact of reduced dust exposure on respiratory health among cement workers: an ecol...
7001056 - Treatment of chronic obstructive pulmonary disease with orally administered theophyllin...
9126796 - Therapeutic effects of diuretics and paracentesis on lung function in patients with non...
16859226 - Effects of theophylline on pulmonary function in patients with traumatic tetraplegia.
10588806 - Developing a register for randomized controlled trials in prosthodontics: results of a ...
10802796 - Creatine monohydrate in muscular dystrophies: a double-blind, placebo-controlled clinic...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  COPD     Volume:  1     ISSN:  1541-2555     ISO Abbreviation:  COPD     Publication Date:  2004  
Date Detail:
Created Date:  2006-12-01     Completed Date:  2006-12-19     Revised Date:  2009-11-17    
Medline Journal Info:
Nlm Unique ID:  101211769     Medline TA:  COPD     Country:  United States    
Other Details:
Languages:  eng     Pagination:  181-90     Citation Subset:  IM    
University of Pennsylvania, eResearch Technology, Inc., Gladwyne, Pennsylvania 19035, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Bronchodilator Agents / administration & dosage,  therapeutic use*
Dose-Response Relationship, Drug
Double-Blind Method
Electrocardiography, Ambulatory*
Follow-Up Studies
Pulmonary Disease, Chronic Obstructive / drug therapy*,  physiopathology*
Retrospective Studies
Scopolamine Derivatives / administration & dosage,  therapeutic use*
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Bronchodilator Agents; 0/Scopolamine Derivatives; 136310-93-5/tiotropium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prevalence and risk factors for chronic obstructive pulmonary disease according to symptoms and spir...
Next Document:  A lung tissue bank for gene expression studies in chronic obstructive pulmonary disease.